Singapore markets closed

GILD Nov 2022 75.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.1000-0.0400 (-28.57%)
As of 02:05PM EDT. Market open.
Full screen
Previous close0.1400
Open0.1700
Bid0.0500
Ask0.3200
Strike75.00
Expiry date2022-11-18
Day's range0.1000 - 0.1700
Contract rangeN/A
Volume16
Open interest2.22k
  • Reuters

    Gilead widens battle against alleged counterfeit HIV drug ring

    A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc HIV drugs, including two alleged "kingpins." Gilead, which has been pursuing alleged counterfeiters in a civil lawsuit since last year, said in a court filing unsealed on Wednesday it had uncovered an operation that was "staggering in scope," responsible for sales of hundreds of millions of dollars of counterfeit bottles of its top sellers Descovy, Genvoya and Biktarvy, and other medicines. U.S. District Judge Ann Donnelly's latest asset freeze order, also unsealed on Wednesday, targets more than 50 defendants newly added to Gilead's lawsuit.

  • Zacks

    Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

    Gilead Sciences (GILD) closed the most recent trading day at $62.63, moving +0.47% from the previous trading session.

  • Motley Fool

    Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond

    Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). AbbVie is one of the largest pharmaceutical companies around. Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them.